Fig. 2

Metabolic phenotyping of rare disseminated tumor cells in MPE. a Illustration of study design and distribution of patient driver oncogene mutations. b Scatter plot generated from the OMC reports 2-NBDG and C12R fluorescence intensity of all CD45^neg cells in MPE sample from P1. The histograms of 2-NBDG and C12R intensities of CD45^pos leukocytes (red) in MPE are shown on the top and right to generate cut-offs for identification of 2-NBDG^high and C12R^high cells (black dots). 2-NBDG^high and C12R^high cells are gated out by five and three standard deviations above mean of CD45^pos leukocytes, respectively. CD45^neg/2-NBDG^low/C12R^low cells are displayed in blue dots. c Representative images of four subsets of CD45^neg cells as well as CD45^pos leukocytes. The images are overlaid by a bright-field image and three fluorescence images (CD45: red; 2-NBDG: green; C12R: blue, scale bar, 30 μm). d The number of CD45^neg, metabolically active cells that are categorized into three subsets across 32 LADC MPE samples. The oncogenic driver mutation associated with each sample is listed. e Relative viability of the two metabolically active cell populations in response to 2-DG and phenformin, respectively, with respect to the DMSO control (n = 2 independent samples, mean ± SD). (*P < 0.05; **P < 0.005). Source data are provided as a Source Data file